Evidence mapPaperPMID 42402629Full record

ReviewSignal transduction and targeted therapy2026

Protein lactylation in health and diseases: molecular mechanisms, biological significance, and clinical implications.

Yue Yang, Ying He, Ziyi Zhang, Yuehua Zhang, Rui Gao, Ke Du, Yuqiang Wu, Ji Wu, Minjie Wei, Mingyan Liu

Abstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yue Yang *Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.ORCID http://orcid.org/0000-0002-3972-2911
Ying He *The First Department of Medical Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Ziyi ZhangDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Yuehua ZhangDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Rui GaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Ke DuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Yuqiang WuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Ji WuShenyang Key Laboratory of Chronic Disease Assessment and Nutritional Intervention for Heart and Brain, Shenyang Medical College, Shenyang, China. wuji@symc.edu.cn.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China. minjie_wei@163.com.
Mingyan LiuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China. saffer@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein lysine lactylation (Kla) is a newly identified post-translational modification (PTM), in which lactyl groups are transferred to specific lysine residues in proteins. As a crucial intermediary between cellular metabolism and epigenetic regulation, Kla immensely increases the functional diversity of the proteome. This intriguing modification extends beyond histones to non-histone proteins, signaling molecules, enzymes, and substrates. In addition to enzymatic L-lactylation utilizing lactate as a lactyl donor and involving enzymes including writers (lactyltransferases), readers (lactylation-binding enzymes), erasers (delactylases), and lactyl-coenzyme A (lactyl-CoA) synthases, non-enzymatic D-lactylation derived from the glyoxalase II substrate S-D-lactoylglutathione (SLG) has also been identified. Emerging evidence underscores the molecular significance of Kla, including gene transcriptional activation, protein stability, enzyme activity, protein‒protein interactions, protein subcellular translocation, crosstalk with other PTMs, RNA modification, epigenetic instability, and phase separation, in orchestrating diverse biological processes. Functionally, Kla plays a fundamental role in physiology, such as somatic cell reprogramming, as well as embryonic, neural, and cochlear development, by regulating gene expression, cell cycle progression, and signal transduction. Conversely, dysregulated Kla renders extensive impacts on the pathogenesis of various diseases, including cancer, neuropsychiatric disorders, cardiovascular and ophthalmic diseases, and immunoinflammatory and metabolic dysregulation, through modulating immune homeostasis, metabolic adaptation, and epigenetic remodeling. This review systematically elucidates the molecular regulatory mechanisms and biological significance of Kla while comprehensively summarizing its involvement in both physiology and pathology. Furthermore, we emphasize the translational potential of Kla as a diagnostic or prognostic biomarker and therapeutic target, offering novel insights for future research and development of innovative therapeutic strategies.

Indexed as

Epigenesis, GeneticLysineProtein Processing, Post-TranslationalAnimalsHumansLysine

Identifiers

PMID42402629
PMCPMC13333863

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.